Results 91 to 100 of about 1,483,959 (183)

JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines

open access: yesExperimental Hematology & Oncology, 2012
Background JAK2V617F, a gain-of-function mutant form of tyrosine kinase JAK2, is found in the majority of patients with Ph- myeloproliferative neoplasms (MPNs), a group of chronic hematological diseases that often lead to acute leukemia.
Zhao Wanke   +4 more
doaj   +1 more source

JAK2V617F-bearing vascular niche enhances malignant hematopoietic regeneration following radiation injury

open access: yesHaematologica, 2018
Myeloproliferative neoplasms are clonal stem cell disorders characterized by hematopoietic stem/progenitor cell expansion. The acquired kinase mutation JAK2V617F plays a central role in these disorders.
Chi Hua Sarah Lin   +3 more
doaj   +1 more source

Comparisions of ARMS-PCR and AS-PCR for the Evaluation of JAK2V617F Mutation in Patients with non-CML Myeloproliferative Neoplasms [PDF]

open access: yesInternational Journal of Hematology-Oncology and Stem Cell Research, 2010
"nBackground and objectives: JAK2 is a nonreceptor tyrosine kinase that plays a major role in myeloid disorders. JAK2V617F mutation is characterized by a G to T transverse at nucleotide 1849 in exon 12 of the JAK2 gene, located on the chromosome 9p,
Parisa Karimzadeh   +11 more
doaj   +2 more sources

JAK2V617F: Is It Sufficient as a Single Player in Splanchnic Venous Thrombosis?

open access: yesCase Reports in Hematology, 2015
Splanchnic venous thrombosis (SVT) includes thrombosis of the hepatic, portal, and mesenteric venous system. Myeloproliferative neoplasms (MPNs) are important factors of SVT in adults.
Pratibha Dhiman, Priyanka Saxena
doaj   +1 more source

Rapid identification of heterozygous or homozygous JAK2V617F mutations in myeloproliferative neoplasms using melting curve analysis

open access: yesJournal of the Formosan Medical Association, 2012
The activating JAK2 mutation with a G-C to T-A transversion at codon 617 (JAK2V617F) is associated with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis.
Ching-Liang Ho   +6 more
doaj   +1 more source

Development of a highly sensitive method for detection of JAK2V617F

open access: yesJournal of Hematology & Oncology, 2011
Background Ph- myeloproliferative neoplasms (MPNs) represent a heterogeneous group of chronic diseases characterized by increased expansion of hematopoietic cells of the myeloid lineage.
Gao Rufei, Zhao Anna H, Zhao Zhizhuang J
doaj   +1 more source

This Is Not a Myeloproliferative Neoplasm…

open access: yes
Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
Stephanie Juané Kennedy
wiley   +1 more source

PO62 | CLINICAL AND MOLECULAR DIAGNOSTIC CHALLENGES IN MYELOPROLIFERATIVE NEOPLASMS WITH LOW JAK2V617F ALLELIC BURDEN

open access: yesBleeding, Thrombosis and Vascular Biology
Introduction. The detection of the JAK2V617F mutation plays a crucial role in diagnosing myeloproliferative neoplasms (MPNs). In clinical practice, a mutation with a VAF greater than 2% is definitively considered positive, a criterion also used to define
Erika Morsia
doaj  

The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy

open access: yesOncoImmunology, 2017
Approximately 90% of patients with the hematological malignancies termed the chronic myeloproliferative neoplasms harbor either the JAK2V617F-mutation or CALR exon 9 mutation.
Morten Orebo Holmström   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy